Tweet
Pathog Glob Health. 2017 Jan 12:1-7. doi: 10.1080/20477724.2016.1275464. [Epub ahead of print]
Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.
Di Mario G1, Soprana E2, Gubinelli F2, Panigada M2, Facchini M1, Fabiani C1, Garulli B3, Basileo M4, Cassone A4, Siccardi A2, Donatelli I1, Castrucci MR1.
Author information
Abstract
BACKGROUND:
Vaccination offers protection against influenza, although current vaccines need to be reformulated each year. The development of a broadly protective influenza vaccine would guarantee the induction of heterosubtypic immunity also against emerging influenza viruses of a novel subtype. Vaccine candidates based on the stalk region of the hemagglutinin (HA) have the potential to induce broad and persistent protection against diverse influenza A viruses.
METHODS:
Modified vaccinia virus Ankara (MVA) expressing a headless HA (hlHA) of A/California/4/09 (CA/09) virus was used as a vaccine to immunize C57BL/6 mice. Specific antibody and cell-mediated immune responses were determined, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus.
RESULTS:
Immunization of mice with CA/09-derived hlHA, vectored by MVA, was able to elicit influenza-specific broad cross-reactive antibodies and cell-mediated immune responses, but failed to induce neutralizing antibodies and did not protect mice against virus challenge.
CONCLUSION:
Although highly immunogenic, our vaccine was unable to induce a protective immunity against influenza. A misfolded and unstable conformation of the hlHA molecule may have affected its capacity of inducing neutralizing antiviral, conformational antibodies. Design of stable hlHA-based immunogens and their delivery by recombinant MVA-based vectors has the potential of improving this promising approach for a universal influenza vaccine.
KEYWORDS:
Influenza virus; MVA vector; antibodies; vaccine
PMID: 28081672 DOI: 10.1080/20477724.2016.1275464
[PubMed - as supplied by publisher]
Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.
Di Mario G1, Soprana E2, Gubinelli F2, Panigada M2, Facchini M1, Fabiani C1, Garulli B3, Basileo M4, Cassone A4, Siccardi A2, Donatelli I1, Castrucci MR1.
Author information
Abstract
BACKGROUND:
Vaccination offers protection against influenza, although current vaccines need to be reformulated each year. The development of a broadly protective influenza vaccine would guarantee the induction of heterosubtypic immunity also against emerging influenza viruses of a novel subtype. Vaccine candidates based on the stalk region of the hemagglutinin (HA) have the potential to induce broad and persistent protection against diverse influenza A viruses.
METHODS:
Modified vaccinia virus Ankara (MVA) expressing a headless HA (hlHA) of A/California/4/09 (CA/09) virus was used as a vaccine to immunize C57BL/6 mice. Specific antibody and cell-mediated immune responses were determined, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus.
RESULTS:
Immunization of mice with CA/09-derived hlHA, vectored by MVA, was able to elicit influenza-specific broad cross-reactive antibodies and cell-mediated immune responses, but failed to induce neutralizing antibodies and did not protect mice against virus challenge.
CONCLUSION:
Although highly immunogenic, our vaccine was unable to induce a protective immunity against influenza. A misfolded and unstable conformation of the hlHA molecule may have affected its capacity of inducing neutralizing antiviral, conformational antibodies. Design of stable hlHA-based immunogens and their delivery by recombinant MVA-based vectors has the potential of improving this promising approach for a universal influenza vaccine.
KEYWORDS:
Influenza virus; MVA vector; antibodies; vaccine
PMID: 28081672 DOI: 10.1080/20477724.2016.1275464
[PubMed - as supplied by publisher]